U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07920783) titled 'A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants' on Oct. 27.
Brief Summary: This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a high-fat meal on the pharmacokinetics of GLR2053.
Study Start Date: Nov. 05
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: GLR2053 Tablets
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of GLR2053.
DRUG: Placebo
Each participant receives...